Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
WINLEVI works differently from any other topical acne treatment
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated
